Accessibility links

Breaking News

Congo Starts First-Ever Trial Testing Ebola Drugs


FILE - Congolese and WHO officials prepare equipment before the launch of vaccination campaign against the deadly Ebola virus near Mangina village, DRC, Aug. 8, 2018. Congo has now begun the first-ever trial to test the effectiveness and safety of four experimental Ebola drugs.

Congo has begun the first-ever trial to test the effectiveness and safety of four experimental Ebola drugs, the first time scientists have directly compared such treatments, the World Health Organization said Monday.

The U.N. health agency described the multi-drug trial as "a giant step" that would "bring clarity about what works best."

"While our focus remains on bringing this outbreak to an end, the launch of the randomized control trial in DRC [Congo] is an important step toward finally finding an Ebola treatment that will save lives," said WHO Director-General Tedros Adhanom Ghebreyesus.

FILE - Dr. Tedros Adhanom Ghebreyesus, WHO director-general, center, speaks to a health official at a newly established Ebola response center in Beni, Democratic Republic of Congo, Aug. 10, 2018.
FILE - Dr. Tedros Adhanom Ghebreyesus, WHO director-general, center, speaks to a health official at a newly established Ebola response center in Beni, Democratic Republic of Congo, Aug. 10, 2018.

Since the beginning of the Ebola outbreak in the North Kivu province in August, four therapeutic drugs have been used to treat patients, namely mAb 114, ZMapp, Remdesivir and Regeneron, according to Congo's Health Ministry.

To date, more than 160 people have been treated with these experimental drugs. Patients won't be treated much differently than before, but scientists will now have a clinical trial framework to collect data on the three antibody treatments and the antiviral.

Congo's Health Ministry said the clinical trial began last week in Beni with Zmapp, mAb 114 and Remdesivir. The test could be extended to other sites and include the fourth medicine, it said. The number of patients who participate "will depend on the evolution of the epidemic and the willingness of patients to participate."

Congo, with poor infrastructure, presents a difficult environment for administering these treatments. ZMapp is difficult to use; it takes three infusions, given over hours. If patients are treated with Remdesivir, their liver function must be analyzed regularly.

FILE - A Congolese health worker administers Ebola vaccine to a boy who had contact with an Ebola sufferer in the village of Mangina in North Kivu province of the Democratic Republic of the Congo, Aug. 18, 2018.
FILE - A Congolese health worker administers Ebola vaccine to a boy who had contact with an Ebola sufferer in the village of Mangina in North Kivu province of the Democratic Republic of the Congo, Aug. 18, 2018.

Because the data collected in the North Kivu epidemic is unlikely to be sufficient for a complete study, the ministry said that the clinical trial may extend over a five-year period to cover several Ebola outbreaks in several countries.

So far in the current outbreak in Congo, there have been 365 confirmed Ebola cases with 189 deaths, according to figures provided by the health ministry Sunday.

FILE - Dr. Oly Ilunga Kalenga, minister of health of the Democratic Republic of Congo, addresses residents at the town all of Mbandaka, May 21, 2018, during the launch of the Ebola vaccination campaign.
FILE - Dr. Oly Ilunga Kalenga, minister of health of the Democratic Republic of Congo, addresses residents at the town all of Mbandaka, May 21, 2018, during the launch of the Ebola vaccination campaign.

"Our country is struck with Ebola outbreaks too often, which also means we have unique expertise in combatting it," said Congo's Minister of Health Dr. Oly Ilunga Kalenga. "These trials will contribute to building that knowledge, while we continue to respond on every front to bring the current outbreak to an end."

This is Congo's tenth outbreak since the virus was identified there in 1976. The outbreak has been plagued by security problems, with health workers attacked by rebels in districts where the virus has been spreading.

XS
SM
MD
LG